SlideShare ist ein Scribd-Unternehmen logo
1 von 41
Small Volume Parenterals
1
Contents…
• Classification,
• Types of vehicles,
• Selection of vehicles and added substance,
• Processing and manufacturing of SVPs,
• Pilot plant scale up for SVPs.
2
Small Volume Parenteral
• According to USP: “ an injection that is packaged in containers labelled as containing
100 ml or less”.
• All the sterile products packaged in vials, ampoules, cartridges, syringes, bottles or
any other container that is 100 ml or less fall under the class of SVP.
• Ophthalmic products packaged in squeezable plastic containers, although topically
applied to the eye rather than administered by injection, also fall under the
classification of Small Volume Injections (SVI) as long as the container size is 100 ml
or less.
• SVP aqueous solutions can be administered by intravenous route because of local
irritation.
3
Small Volume Parenteral
• Small volume parenteral products can be formulated and packaged in several
ways and include a wide variety of products like:
• Pharmaceutical products, Biological products, Allergenic extracts,
Radiopharmaceutical products, Genetically engineered or biotechnology
products, Liposome and lipid products.
• An injection is a preparation intended for parenteral administration and/or
for constituting or diluting a parenteral article prior to administration.
4
Small Volume Parenteral
• Types of preparations:-
• Drug injection
• Drug for injection
• Drug injectable emulsion
• Drug injectable suspension
• Drug for injectable suspension
5
Classification of SVP
• Single dose ampoules (glass/plastic),
• Single dose vials
• Multiple dose vials,
• Prefilled syringes.
6
Single Dose Ampoules
• A single-dose or single-use vial is a vial of liquid medication intended for parenteral
administration (injection or infusion) that is meant for use in a single patient for a
single case, procedure, injection.
• Single-dose or single-use vials are labeled as such by the manufacturer and typically
lack an antimicrobial preservative.
• Vials that are labeled as single-dose or single-use should be used for only a single
patient as part of a single case, procedure, injection.
7
Single Dose Vials
• A Single-Dose Vial (SDV) is approved for use on a single patient for a single
procedure or injection.
• SDVs typically lack an antimicrobial preservative.
• Do not save leftover medication from these vials.
• Harmful bacteria can grow and infect a patient.
• Discard after every use!
8
Multiple Dose Vials
• A Multiple-dose Vial (MDV) is recognized by its FDA-approved label.
• MDVs can be used for more than one patient when aseptic technique is followed,
ideally even MDVs are used for only one patient.
• MDVs typically contain an antimicrobial preservative to help limit the growth of
bacteria.
• Preservatives have no effect on bloodborne viruses (i.e. hepatitis B, hepatitis C, HIV).
• Discard MDVs when the beyond-use date has been reached, when doses are drawn
in a patient treatment area, or any time the sterility of the vial is in question!
9
Prefilled syringes
✓ A prefilled syringe is a single-dose packet of parental drug to which a needle has
been fixed by the manufacturer.
✓ Prefillable syringes have become an increasingly important option in the
packaging and delivery of injectable drug products.
✓ Humira®, Enbrel®, Copaxone®, Lovenox® and Rebif® are examples of
blockbuster drugs that are being extensively administered via prefilled syringes
10
Vehicles for Injection
• Aqueous vehicles:
• Frequently, isotonic (to blood) to which drug may be added at time of use.
• Water-miscible vehicles:
• Portion of the vehicle in the formulation,
• used primarily to effect solubility of drugs and/or reduce hydrolysis
• ethyl alcohol; polyethylene glycol (liquid) and propylene glycol
• Nonaqueous vehicles:
• Fixed oils (vegetable origin, and rancid resistance) used in hormone preparations
11
Aqueous vehicles
• Water for Injection (WFI) USP
• Sterile Water for Injection (SWFI)
• Bacteriostatic Water for Injection USP
• Sterile Water for Irrigation USP
• Sterile Water for Inhalation USP
12
Water for Injection (WFI) USP
• Highly purified water used as a vehicle for injectable preparations which will be
subsequently sterilized.
• USP requirement: NMT 10 ppm (1 mg/100 ml) of total solids.
• pH of 5.0 – 7.0 .
• WFI may be prepared by either distillation or reverse osmosis.
• Stored in chemically resistant tank.
• Used as solvent for preparation of parenteral solutions.
• It is not required to be sterilized and pyrogen free.
• It is intended to be used within 24 hours after collection.
• The water should be collected in sterile and pyrogen free containers.
13
Specifications for WFI as per USP
Sterile Water for Injection (SWFI)
• Sterile Water for Injection is Water for Injection packaged and rendered sterile.
• Is water for injection that is sterilized and packaged in single dose container of type1 and 2 glass.
• It is used for extemporaneous prescription compounding and as a sterile diluent for parenteral
products.
• It may also be used for other applications when
• Access to a validated water system is not practical, or
• Where only a relatively small quantity is needed.
• Sterile Water for Injection is packaged in single-dose containers not larger than 1 L.
• Multiple- dose containers not exceeding 30 ml.
• They are permitted to contain higher levels of solid than WFI because of possible leaching.
• Used for washing wounds, surgical incisions or body tissues. 14
Why TDS in
SWFI is more
than WFI?
Bacteriostatic Water for Injection USP
• Water for Injection, packaged and rendered sterile, to which one or more suitable
antimicrobial preservatives are added or Is sterile water for injection that contains
one or more suitable antimicrobial agents.
• Sterile water containing 0.9% benzyl alcohol that is used to dilute or dissolve
medications.
• It is intended to be used as a diluent in the preparation of parenteral products.
• These are typically for multi-dose products that require repeated content
withdrawals.
• It also packaged in single or multiple dose container of type 1 and 2 glass.
• It may be packaged in single-dose or multiple-dose containers not larger than 30 mL. 15
Sterile Water for Irrigation USP
• Water for Injection packaged and sterilized in single-dose containers which
may be larger than 1 L.
• Is water for injection that is sterilized and suitably packaged.
• They allow rapid delivery of their contents.
• Due to its usage, Sterile Water for Irrigation is not required to meet Particulate
Matter in Injections.
• It contains no antimicrobial agents or other added substances.
16
Sterile Water for Inhalation USP
• Is Water for Injection that is packaged and rendered sterile.
• It is intended for use in inhalators and in the preparation of inhalation
solutions.
• This monograph has no requirement to meet.
• It carries a less stringent specification for bacterial endotoxins than Sterile
Water for Injection.
• Therefore is not suitable for parenteral applications.
17
Water-miscible vehicles
• A number of solvents that are miscible with water have been used as a portion
of the vehicle in the formulation of parenterals.
• These solvents are used to solubilize certain drugs in an aqueous vehicle and
to reduce hydrolysis.
• The most important solvents in this group are ethyl alcohol, liquid
polyethylene glycol and propylene glycol.
• Ethyl alcohol is used in the preparation of solutions of cardiac glycosides and
the glycols in solutions of barbiturates, certain alkaloids, and certain
antibiotics.
• Such preparations are given intramuscularly.
18
Water-miscible vehicles
• There are limitations with the amount of these co-solvents that can be
administered, due to toxicity concerns, greater potential for
hemolysis, and potential for drug precipitation at the site of injection.
• Formulation scientists needing to use one or more of these solvents
must consult the literature and toxicologists to ascertain the
maximum amount of co-solvents allowed for their particular product.
19
Non-Aqueous Vehicles
• The most important group of non-aqueous vehicles is the fixed oils.
• The USP provides specifications for such vehicles, indicating that the fixed oils must
be of vegetable origin so they will metabolize, will be liquid at room temperature,
and will not become rancid readily.
• The USP also specifies limits for the free fatty acid content, iodine value, and
saponification value (oil heated with alkali to produce soap, i.e., alcohol plus acid
salt).
• The oils most commonly used are corn oil, cottonseed oil, peanut oil, and sesame oil.
20
Non-Aqueous Vehicles
• Fixed oils are used as vehicles for certain hormone (e.g., progesterone,
testosterone, deoxycorticosterone) and vitamin (e.g., Vitamin K,
Vitamin E) preparations.
• The label must state the name of the vehicle, so the user may beware
in case of known sensitivity or other reactions to it.
21
22
Antimicrobials
• Added for fungistatic or bacteriostat action or concentration.
• Used to prevent the multiplication of micro-organisms.
• Examples:
• Benzyl alcohol -- 0.5 – 10 %
• Benzethonium chloride -- 0.01 %
• Methyl paraben -- 0.01 – 0.18 %
• Propyl paraben -- 0.005 – 0.035 %
• Phenol -- 0.065 – 0.5 %
Preservatives
 Multidose containers must have
preservatives unless prohibited by
monograph.
 Large volume parenteral must not
contain preservative b’coz it may
be dangerous to human body if it
contain in high doses.
23
Antioxidants
• Used to protect product from oxidation.
• Acts as reducing agent or prevents oxidation.
A) Reducing agent:
 Ascorbic acid -- 0.02 – 0.1 %
 Sodium bisulphate -- 0.1 – 0.15 %
 Sod. Metabisulphite -- 0.1 – 0.15 %
 Thiourea -- 0.005 %
C) Synergistic:
 Ascorbic acid ,
 Citric acid ,
 Tartaric acid.
B) Blocking agents:
 Ascorbic acid esters -- 0.01 – 0.015%
 BHT -- 0.005 – 0.02 %
D) Chelating agent:
 EDTA -- 0.01- 0.075 %
Example
24
Buffers• Added to maintain pH,
• Change in pH may causes degradation of the products
• Acetates, citrates, phosphates are generally used.
Factors affecting selection of buffers:
• Effective range,
• Concentration
• Chemical effect on the total product
Examples:
• Acetic acid, adipic acid, benzoic acid, citric acid, lactic acid
• Used in the conc. of 0.1 to 5.0 %
25
Stabilizers
• As parenterals are available in solution form they are most prone to unstabilize.
• Used to stabilize the formulation
• Maintain stable
Examples:
• Creatinine – 0.5- 0.8 %
• Glycerin – 1.5 – 2.25 %
• Niacinamide – 1.25 -2.5 %
• Sodium saccharin – 0.03 %
• Sodium caprylate – 0.4 %
26
Chelating agents
• Used to form the complex with the metallic ions present in the formulation so that the
ions will not interfere during mfg. of formulation.
• They form a complex which gets dissolved in the solvents.
Examples:
• Disodium edetate – 0.00368 - 0.05 %
• Disodium calcium edetate - 0.04 %
27
Solubilizing agents
• Used to increase solubility of slightly soluble drugs
• They acts by any one of the following:
• Solubilizers,
• Emulsifiers or
• Wetting agents.
Examples:
• Dimethylacetamide, Ethyl alcohol, Glycerine, Lecithin, PEG – 40 + Castor oil, PEG – 300,
Polysorbate 20, 40, 80
28
Inert gases
• Another means of enhancing the product integrity of oxygen sensitive medicaments is
by displacing the air the solution with nitrogen or argon.
• This technique may be made more effective by first purging with nitrogen or boiling
the water to reduce dissolved oxygen.
• The container is also purged with nitrogen or argon before filling and may also be
topped off with gas before sealing.
29
Tonicity adjusting agents
• Used to reduce the pain of injection.
• Buffers may acts as tonicity contributor as well as stabilizers for the pH.
• Isotonicity depends on permeability of a living semipermeable membrane
• Hypotonic : swelling of cells (enlargement)
• Hypertonic: shrinking of cells (reduction)
Examples:
• Glycerin, Lactose, Mannitol, Dextrose, Sodium chloride, Sorbitol
30
Surfactants
• Used:
• to dispose a water-insoluble drug as a colloidal dispersion.
• for wetting powder.
• to prevent crystal growth in a suspension.
• to provide acceptable syringability.
• for Solubilizing steroids and fat-soluble vitamins.
• Example:
• Polyethylene 0.1 to 0.5%
• Sorbitan monooleate 0.05 to 0.25%
31
Protectants
• Used to protect against loss of activity caused by some stress
• Used to prevent loss of active ingredients by adsorption to process equipment or
to primary packaging materials
• Protectants primarily used in protein formulations.
Examples:
• Sucrose, glucose, lactose, maltose, trehalose (2 to 5%)
• Human serum albumin (0.1 to 1%)
Processing and manufacturing of SVPs
• The production area where the parenteral preparation are
manufactured can be divided into five sections:
• Clean-up area
• Preparation area
• Aseptic area
• Quarantine area
• Finishing & packaging area
32
Layout showing various activities in
parenteral manufacturing
33
Clean- up area
• Non aseptic area.
• Free from dust, fibers and micro-organisms.
• Constructed in such a way that should withstand moisture, steam and detergent.
• Ceiling and walls are coated with material to prevent accumulation of dust and micro-organisms.
• Exhaust fans are fitted to remove heat and humidity.
• The area should be kept clean so as to avoid contamination to aseptic area.
• The containers and closures are washed and dried in this area.
34
Preparation area
• The ingredients are mixed and preparation is prepared for filling.
• Not essential that the area is aseptic.
• Strict precaution is taken to prevent contamination from outside.
• Cabinets and counters: SS.
• Ceiling and walls : sealed and painted.
35
Aseptic area
• Filtration and filling into final containers and sealing is done.
• The entry of outside person is strictly prohibited.
• To maintain sterility, special trained persons are only allowed to enter and work.
• Person who worked should wear sterile cloths.
• Should be subjected for physical examination to ensure the fitness.
• Minimum movement should be there in this area.
• Ceiling and walls and floors : sealed and painted or treated with aseptic solution and there should not
be any toxic effect of this treatment.
• Cabinets and counters: SS.
• Mechanical equipments : SS. 36
Air in aseptic area
• Free from fibers, dust and micro organisms.
• HEPA filters are used which removes particles upto 0.3 micron.
• Fitted in laminar air flow system, in which air is free from dust and micro
organisms flows with uniform velocity.
• Air supplied is under positive pressure which prevents particulate contamination
from sweeping.
• UV lamps are fitted to maintain sterility.
37
Quarantine area
• After filling, sealing and sterilization the products or batch is kept in this
area.
• The random samples are chosen and given for analysis to QC dept.
• The batch is send to packing after issuing satisfactory reports of analysis
from QC.
• If any problem is observed in above analysis the decision is to be taken for
reprocessing or others.
38
Finishing and packaging area
• After proper label, the product is given for packing.
• Packing is done to protect the product from external environment.
• The ideal Packing is that which protects the product during transportation,
storage, shipping and handling.
• The labeled container should be packed in cardboard or plastic containers.
• Ampoules should be packed in partitioned boxes.
39
Stainless steel used in Pharm. Industry
40
Stainless steel used in Pharm. Industry
41

Weitere ähnliche Inhalte

Was ist angesagt?

Supac - Guidance for Immediate Release Dosage Form
Supac - Guidance for Immediate Release Dosage FormSupac - Guidance for Immediate Release Dosage Form
Supac - Guidance for Immediate Release Dosage FormJubiliant Generics Limited
 
IPQC for capsule.
IPQC for capsule.IPQC for capsule.
IPQC for capsule.ganpat420
 
Evaluation of capsules
Evaluation of capsules Evaluation of capsules
Evaluation of capsules SHAHINALAM360
 
Drug excipient Compatibility
Drug excipient CompatibilityDrug excipient Compatibility
Drug excipient CompatibilitySuraj Choudhary
 
Formulation and development of parenterals
Formulation and development of parenteralsFormulation and development of parenterals
Formulation and development of parenteralsSai Datri Arige
 
Non clinical drug development. ppt
Non clinical drug development. pptNon clinical drug development. ppt
Non clinical drug development. pptPRABU12345678
 
Preformulation testing of solid dosage forms
Preformulation testing of solid dosage formsPreformulation testing of solid dosage forms
Preformulation testing of solid dosage formsSunil Boreddy Rx
 
microspheres types , preparation and evaluation
microspheres types , preparation and evaluationmicrospheres types , preparation and evaluation
microspheres types , preparation and evaluationSowjanya
 
Preparation & stability of large & small volume parentrals
Preparation & stability of large & small volume parentralsPreparation & stability of large & small volume parentrals
Preparation & stability of large & small volume parentralsROHIT
 
Evaluation of parenterals
Evaluation of parenteralsEvaluation of parenterals
Evaluation of parenteralsmonikapawar306
 
Implant : Challenging Drug Delivery System
Implant : Challenging Drug Delivery SystemImplant : Challenging Drug Delivery System
Implant : Challenging Drug Delivery Systembiniyapatel
 
Physics of tablet compression
Physics of tablet compressionPhysics of tablet compression
Physics of tablet compressionMahadev Birajdar
 
DISSOLUTION TESTING APPARATUS
DISSOLUTION TESTING APPARATUSDISSOLUTION TESTING APPARATUS
DISSOLUTION TESTING APPARATUSBushra S
 
Scale up and post approval changes(supac)
Scale up and post approval changes(supac)Scale up and post approval changes(supac)
Scale up and post approval changes(supac)bdvfgbdhg
 
Quality control test of tablets
Quality control test of tabletsQuality control test of tablets
Quality control test of tabletsTanmayPanigrahy
 
Buccal Drug Delivery System
Buccal Drug Delivery SystemBuccal Drug Delivery System
Buccal Drug Delivery SystemMOHAMMAD ASIM
 
Invitro : dissolution and drug release testing
Invitro : dissolution and drug release testingInvitro : dissolution and drug release testing
Invitro : dissolution and drug release testingDurgadevi Ganesan
 
Bioadhesive drug delivery system
Bioadhesive drug delivery systemBioadhesive drug delivery system
Bioadhesive drug delivery systemDr. Shreeraj Shah
 

Was ist angesagt? (20)

Parenteral formulations
Parenteral formulationsParenteral formulations
Parenteral formulations
 
Supac - Guidance for Immediate Release Dosage Form
Supac - Guidance for Immediate Release Dosage FormSupac - Guidance for Immediate Release Dosage Form
Supac - Guidance for Immediate Release Dosage Form
 
IPQC for capsule.
IPQC for capsule.IPQC for capsule.
IPQC for capsule.
 
Evaluation of capsules
Evaluation of capsules Evaluation of capsules
Evaluation of capsules
 
Drug excipient Compatibility
Drug excipient CompatibilityDrug excipient Compatibility
Drug excipient Compatibility
 
Formulation and development of parenterals
Formulation and development of parenteralsFormulation and development of parenterals
Formulation and development of parenterals
 
Non clinical drug development. ppt
Non clinical drug development. pptNon clinical drug development. ppt
Non clinical drug development. ppt
 
Preformulation testing of solid dosage forms
Preformulation testing of solid dosage formsPreformulation testing of solid dosage forms
Preformulation testing of solid dosage forms
 
microspheres types , preparation and evaluation
microspheres types , preparation and evaluationmicrospheres types , preparation and evaluation
microspheres types , preparation and evaluation
 
Preparation & stability of large & small volume parentrals
Preparation & stability of large & small volume parentralsPreparation & stability of large & small volume parentrals
Preparation & stability of large & small volume parentrals
 
Supac
SupacSupac
Supac
 
Evaluation of parenterals
Evaluation of parenteralsEvaluation of parenterals
Evaluation of parenterals
 
Implant : Challenging Drug Delivery System
Implant : Challenging Drug Delivery SystemImplant : Challenging Drug Delivery System
Implant : Challenging Drug Delivery System
 
Physics of tablet compression
Physics of tablet compressionPhysics of tablet compression
Physics of tablet compression
 
DISSOLUTION TESTING APPARATUS
DISSOLUTION TESTING APPARATUSDISSOLUTION TESTING APPARATUS
DISSOLUTION TESTING APPARATUS
 
Scale up and post approval changes(supac)
Scale up and post approval changes(supac)Scale up and post approval changes(supac)
Scale up and post approval changes(supac)
 
Quality control test of tablets
Quality control test of tabletsQuality control test of tablets
Quality control test of tablets
 
Buccal Drug Delivery System
Buccal Drug Delivery SystemBuccal Drug Delivery System
Buccal Drug Delivery System
 
Invitro : dissolution and drug release testing
Invitro : dissolution and drug release testingInvitro : dissolution and drug release testing
Invitro : dissolution and drug release testing
 
Bioadhesive drug delivery system
Bioadhesive drug delivery systemBioadhesive drug delivery system
Bioadhesive drug delivery system
 

Ähnlich wie Small volume parenterals

PARENTERAL ROUTES OF DRUG ADMINISTRATION
PARENTERAL ROUTES OF DRUG ADMINISTRATIONPARENTERAL ROUTES OF DRUG ADMINISTRATION
PARENTERAL ROUTES OF DRUG ADMINISTRATIONZainab Riaz
 
Types of Parenteral Formulation
Types of Parenteral FormulationTypes of Parenteral Formulation
Types of Parenteral FormulationNIDHIBANSAL65
 
Sterile dosage forms: Parenterals
Sterile dosage forms: ParenteralsSterile dosage forms: Parenterals
Sterile dosage forms: ParenteralsParag Jain
 
11 sterile dosage form
11 sterile dosage form11 sterile dosage form
11 sterile dosage formPradeep Patil
 
5 Parenteral preparations; Formulation and packaging.pdf
5 Parenteral preparations; Formulation and packaging.pdf5 Parenteral preparations; Formulation and packaging.pdf
5 Parenteral preparations; Formulation and packaging.pdfSaqibTeli1
 
eye drop and ointment.ppt
eye drop and ointment.ppteye drop and ointment.ppt
eye drop and ointment.pptKoushalDhamija1
 
Parenteral drug delivery
Parenteral drug deliveryParenteral drug delivery
Parenteral drug deliveryRavish Yadav
 

Ähnlich wie Small volume parenterals (20)

PARENTERAL ROUTES OF DRUG ADMINISTRATION
PARENTERAL ROUTES OF DRUG ADMINISTRATIONPARENTERAL ROUTES OF DRUG ADMINISTRATION
PARENTERAL ROUTES OF DRUG ADMINISTRATION
 
General requirements of parenteral preparations
General requirements of parenteral preparationsGeneral requirements of parenteral preparations
General requirements of parenteral preparations
 
Types of Parenteral Formulation
Types of Parenteral FormulationTypes of Parenteral Formulation
Types of Parenteral Formulation
 
Types of parenteral formulations
Types of parenteral formulationsTypes of parenteral formulations
Types of parenteral formulations
 
Sterile dosage forms: Parenterals
Sterile dosage forms: ParenteralsSterile dosage forms: Parenterals
Sterile dosage forms: Parenterals
 
Sterile dosage form
Sterile dosage formSterile dosage form
Sterile dosage form
 
Parenteral drug delivery
Parenteral drug deliveryParenteral drug delivery
Parenteral drug delivery
 
11 sterile dosage form
11 sterile dosage form11 sterile dosage form
11 sterile dosage form
 
5 Parenteral preparations; Formulation and packaging.pdf
5 Parenteral preparations; Formulation and packaging.pdf5 Parenteral preparations; Formulation and packaging.pdf
5 Parenteral preparations; Formulation and packaging.pdf
 
Solutions.pptx
Solutions.pptxSolutions.pptx
Solutions.pptx
 
Solutions
SolutionsSolutions
Solutions
 
Parenteral by SV Deshmane
Parenteral by SV DeshmaneParenteral by SV Deshmane
Parenteral by SV Deshmane
 
Parenteral products Part- I
Parenteral products  Part- IParenteral products  Part- I
Parenteral products Part- I
 
eye drop and ointment.ppt
eye drop and ointment.ppteye drop and ointment.ppt
eye drop and ointment.ppt
 
Parenteral drug delivery
Parenteral drug deliveryParenteral drug delivery
Parenteral drug delivery
 
Parenterals
ParenteralsParenterals
Parenterals
 
Parenteral Products.pptx
Parenteral Products.pptxParenteral Products.pptx
Parenteral Products.pptx
 
PARENTERAL PRODUCTS
PARENTERAL PRODUCTSPARENTERAL PRODUCTS
PARENTERAL PRODUCTS
 
Additive substances for parenterals
Additive substances for parenteralsAdditive substances for parenterals
Additive substances for parenterals
 
Parenteral products
Parenteral productsParenteral products
Parenteral products
 

Mehr von Dr. Prashant L. Pingale GES's Sir Dr. M. S. Gosavi College of Pharmacy, Nashik

Mehr von Dr. Prashant L. Pingale GES's Sir Dr. M. S. Gosavi College of Pharmacy, Nashik (20)

Targeted drug delivery
Targeted drug delivery Targeted drug delivery
Targeted drug delivery
 
Ophthalmic Drug Delivery System
Ophthalmic Drug Delivery SystemOphthalmic Drug Delivery System
Ophthalmic Drug Delivery System
 
Transdermal drug delivery system
Transdermal drug delivery systemTransdermal drug delivery system
Transdermal drug delivery system
 
Polymers in controlled release Drug Delivery System
Polymers in controlled release Drug Delivery SystemPolymers in controlled release Drug Delivery System
Polymers in controlled release Drug Delivery System
 
Nasopulmonary Drug Delivery System
Nasopulmonary Drug Delivery SystemNasopulmonary Drug Delivery System
Nasopulmonary Drug Delivery System
 
Mucoadhesive Drug Delivery System
Mucoadhesive Drug Delivery SystemMucoadhesive Drug Delivery System
Mucoadhesive Drug Delivery System
 
Microencapsulation
MicroencapsulationMicroencapsulation
Microencapsulation
 
Implantable Drug Delivery System
Implantable Drug Delivery SystemImplantable Drug Delivery System
Implantable Drug Delivery System
 
Gastroretentive Drug Delivery System
Gastroretentive Drug Delivery SystemGastroretentive Drug Delivery System
Gastroretentive Drug Delivery System
 
Lyophillization
LyophillizationLyophillization
Lyophillization
 
Large volume parenterals
Large volume parenteralsLarge volume parenterals
Large volume parenterals
 
Sterile formulations
Sterile formulationsSterile formulations
Sterile formulations
 
Ophthalmic drug delivery system
Ophthalmic drug delivery systemOphthalmic drug delivery system
Ophthalmic drug delivery system
 
Pilot plant scale up for Small Volume Parenterals
Pilot plant scale up for Small Volume Parenterals Pilot plant scale up for Small Volume Parenterals
Pilot plant scale up for Small Volume Parenterals
 
Right to information act
Right to information actRight to information act
Right to information act
 
GMP design of parenteral production facility
GMP design of parenteral production facilityGMP design of parenteral production facility
GMP design of parenteral production facility
 
Prefilled syringes
Prefilled syringesPrefilled syringes
Prefilled syringes
 
Blow fill seal technology
Blow fill seal technologyBlow fill seal technology
Blow fill seal technology
 
Solubility of drugs
Solubility of drugsSolubility of drugs
Solubility of drugs
 
States of matter
States of matterStates of matter
States of matter
 

Kürzlich hochgeladen

Key note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdfKey note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdfAdmir Softic
 
How to Create and Manage Wizard in Odoo 17
How to Create and Manage Wizard in Odoo 17How to Create and Manage Wizard in Odoo 17
How to Create and Manage Wizard in Odoo 17Celine George
 
This PowerPoint helps students to consider the concept of infinity.
This PowerPoint helps students to consider the concept of infinity.This PowerPoint helps students to consider the concept of infinity.
This PowerPoint helps students to consider the concept of infinity.christianmathematics
 
REMIFENTANIL: An Ultra short acting opioid.pptx
REMIFENTANIL: An Ultra short acting opioid.pptxREMIFENTANIL: An Ultra short acting opioid.pptx
REMIFENTANIL: An Ultra short acting opioid.pptxDr. Ravikiran H M Gowda
 
Interdisciplinary_Insights_Data_Collection_Methods.pptx
Interdisciplinary_Insights_Data_Collection_Methods.pptxInterdisciplinary_Insights_Data_Collection_Methods.pptx
Interdisciplinary_Insights_Data_Collection_Methods.pptxPooja Bhuva
 
Beyond_Borders_Understanding_Anime_and_Manga_Fandom_A_Comprehensive_Audience_...
Beyond_Borders_Understanding_Anime_and_Manga_Fandom_A_Comprehensive_Audience_...Beyond_Borders_Understanding_Anime_and_Manga_Fandom_A_Comprehensive_Audience_...
Beyond_Borders_Understanding_Anime_and_Manga_Fandom_A_Comprehensive_Audience_...Pooja Bhuva
 
Understanding Accommodations and Modifications
Understanding  Accommodations and ModificationsUnderstanding  Accommodations and Modifications
Understanding Accommodations and ModificationsMJDuyan
 
Towards a code of practice for AI in AT.pptx
Towards a code of practice for AI in AT.pptxTowards a code of practice for AI in AT.pptx
Towards a code of practice for AI in AT.pptxJisc
 
Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...
Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...
Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...Pooja Bhuva
 
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...Nguyen Thanh Tu Collection
 
On_Translating_a_Tamil_Poem_by_A_K_Ramanujan.pptx
On_Translating_a_Tamil_Poem_by_A_K_Ramanujan.pptxOn_Translating_a_Tamil_Poem_by_A_K_Ramanujan.pptx
On_Translating_a_Tamil_Poem_by_A_K_Ramanujan.pptxPooja Bhuva
 
How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17Celine George
 
HMCS Vancouver Pre-Deployment Brief - May 2024 (Web Version).pptx
HMCS Vancouver Pre-Deployment Brief - May 2024 (Web Version).pptxHMCS Vancouver Pre-Deployment Brief - May 2024 (Web Version).pptx
HMCS Vancouver Pre-Deployment Brief - May 2024 (Web Version).pptxmarlenawright1
 
ICT Role in 21st Century Education & its Challenges.pptx
ICT Role in 21st Century Education & its Challenges.pptxICT Role in 21st Century Education & its Challenges.pptx
ICT Role in 21st Century Education & its Challenges.pptxAreebaZafar22
 
The basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptxThe basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptxheathfieldcps1
 
Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptxBasic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptxDenish Jangid
 
Graduate Outcomes Presentation Slides - English
Graduate Outcomes Presentation Slides - EnglishGraduate Outcomes Presentation Slides - English
Graduate Outcomes Presentation Slides - Englishneillewis46
 
Exploring_the_Narrative_Style_of_Amitav_Ghoshs_Gun_Island.pptx
Exploring_the_Narrative_Style_of_Amitav_Ghoshs_Gun_Island.pptxExploring_the_Narrative_Style_of_Amitav_Ghoshs_Gun_Island.pptx
Exploring_the_Narrative_Style_of_Amitav_Ghoshs_Gun_Island.pptxPooja Bhuva
 
SOC 101 Demonstration of Learning Presentation
SOC 101 Demonstration of Learning PresentationSOC 101 Demonstration of Learning Presentation
SOC 101 Demonstration of Learning Presentationcamerronhm
 
NO1 Top Black Magic Specialist In Lahore Black magic In Pakistan Kala Ilam Ex...
NO1 Top Black Magic Specialist In Lahore Black magic In Pakistan Kala Ilam Ex...NO1 Top Black Magic Specialist In Lahore Black magic In Pakistan Kala Ilam Ex...
NO1 Top Black Magic Specialist In Lahore Black magic In Pakistan Kala Ilam Ex...Amil baba
 

Kürzlich hochgeladen (20)

Key note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdfKey note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdf
 
How to Create and Manage Wizard in Odoo 17
How to Create and Manage Wizard in Odoo 17How to Create and Manage Wizard in Odoo 17
How to Create and Manage Wizard in Odoo 17
 
This PowerPoint helps students to consider the concept of infinity.
This PowerPoint helps students to consider the concept of infinity.This PowerPoint helps students to consider the concept of infinity.
This PowerPoint helps students to consider the concept of infinity.
 
REMIFENTANIL: An Ultra short acting opioid.pptx
REMIFENTANIL: An Ultra short acting opioid.pptxREMIFENTANIL: An Ultra short acting opioid.pptx
REMIFENTANIL: An Ultra short acting opioid.pptx
 
Interdisciplinary_Insights_Data_Collection_Methods.pptx
Interdisciplinary_Insights_Data_Collection_Methods.pptxInterdisciplinary_Insights_Data_Collection_Methods.pptx
Interdisciplinary_Insights_Data_Collection_Methods.pptx
 
Beyond_Borders_Understanding_Anime_and_Manga_Fandom_A_Comprehensive_Audience_...
Beyond_Borders_Understanding_Anime_and_Manga_Fandom_A_Comprehensive_Audience_...Beyond_Borders_Understanding_Anime_and_Manga_Fandom_A_Comprehensive_Audience_...
Beyond_Borders_Understanding_Anime_and_Manga_Fandom_A_Comprehensive_Audience_...
 
Understanding Accommodations and Modifications
Understanding  Accommodations and ModificationsUnderstanding  Accommodations and Modifications
Understanding Accommodations and Modifications
 
Towards a code of practice for AI in AT.pptx
Towards a code of practice for AI in AT.pptxTowards a code of practice for AI in AT.pptx
Towards a code of practice for AI in AT.pptx
 
Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...
Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...
Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...
 
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
 
On_Translating_a_Tamil_Poem_by_A_K_Ramanujan.pptx
On_Translating_a_Tamil_Poem_by_A_K_Ramanujan.pptxOn_Translating_a_Tamil_Poem_by_A_K_Ramanujan.pptx
On_Translating_a_Tamil_Poem_by_A_K_Ramanujan.pptx
 
How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17
 
HMCS Vancouver Pre-Deployment Brief - May 2024 (Web Version).pptx
HMCS Vancouver Pre-Deployment Brief - May 2024 (Web Version).pptxHMCS Vancouver Pre-Deployment Brief - May 2024 (Web Version).pptx
HMCS Vancouver Pre-Deployment Brief - May 2024 (Web Version).pptx
 
ICT Role in 21st Century Education & its Challenges.pptx
ICT Role in 21st Century Education & its Challenges.pptxICT Role in 21st Century Education & its Challenges.pptx
ICT Role in 21st Century Education & its Challenges.pptx
 
The basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptxThe basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptx
 
Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptxBasic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
 
Graduate Outcomes Presentation Slides - English
Graduate Outcomes Presentation Slides - EnglishGraduate Outcomes Presentation Slides - English
Graduate Outcomes Presentation Slides - English
 
Exploring_the_Narrative_Style_of_Amitav_Ghoshs_Gun_Island.pptx
Exploring_the_Narrative_Style_of_Amitav_Ghoshs_Gun_Island.pptxExploring_the_Narrative_Style_of_Amitav_Ghoshs_Gun_Island.pptx
Exploring_the_Narrative_Style_of_Amitav_Ghoshs_Gun_Island.pptx
 
SOC 101 Demonstration of Learning Presentation
SOC 101 Demonstration of Learning PresentationSOC 101 Demonstration of Learning Presentation
SOC 101 Demonstration of Learning Presentation
 
NO1 Top Black Magic Specialist In Lahore Black magic In Pakistan Kala Ilam Ex...
NO1 Top Black Magic Specialist In Lahore Black magic In Pakistan Kala Ilam Ex...NO1 Top Black Magic Specialist In Lahore Black magic In Pakistan Kala Ilam Ex...
NO1 Top Black Magic Specialist In Lahore Black magic In Pakistan Kala Ilam Ex...
 

Small volume parenterals

  • 2. Contents… • Classification, • Types of vehicles, • Selection of vehicles and added substance, • Processing and manufacturing of SVPs, • Pilot plant scale up for SVPs. 2
  • 3. Small Volume Parenteral • According to USP: “ an injection that is packaged in containers labelled as containing 100 ml or less”. • All the sterile products packaged in vials, ampoules, cartridges, syringes, bottles or any other container that is 100 ml or less fall under the class of SVP. • Ophthalmic products packaged in squeezable plastic containers, although topically applied to the eye rather than administered by injection, also fall under the classification of Small Volume Injections (SVI) as long as the container size is 100 ml or less. • SVP aqueous solutions can be administered by intravenous route because of local irritation. 3
  • 4. Small Volume Parenteral • Small volume parenteral products can be formulated and packaged in several ways and include a wide variety of products like: • Pharmaceutical products, Biological products, Allergenic extracts, Radiopharmaceutical products, Genetically engineered or biotechnology products, Liposome and lipid products. • An injection is a preparation intended for parenteral administration and/or for constituting or diluting a parenteral article prior to administration. 4
  • 5. Small Volume Parenteral • Types of preparations:- • Drug injection • Drug for injection • Drug injectable emulsion • Drug injectable suspension • Drug for injectable suspension 5
  • 6. Classification of SVP • Single dose ampoules (glass/plastic), • Single dose vials • Multiple dose vials, • Prefilled syringes. 6
  • 7. Single Dose Ampoules • A single-dose or single-use vial is a vial of liquid medication intended for parenteral administration (injection or infusion) that is meant for use in a single patient for a single case, procedure, injection. • Single-dose or single-use vials are labeled as such by the manufacturer and typically lack an antimicrobial preservative. • Vials that are labeled as single-dose or single-use should be used for only a single patient as part of a single case, procedure, injection. 7
  • 8. Single Dose Vials • A Single-Dose Vial (SDV) is approved for use on a single patient for a single procedure or injection. • SDVs typically lack an antimicrobial preservative. • Do not save leftover medication from these vials. • Harmful bacteria can grow and infect a patient. • Discard after every use! 8
  • 9. Multiple Dose Vials • A Multiple-dose Vial (MDV) is recognized by its FDA-approved label. • MDVs can be used for more than one patient when aseptic technique is followed, ideally even MDVs are used for only one patient. • MDVs typically contain an antimicrobial preservative to help limit the growth of bacteria. • Preservatives have no effect on bloodborne viruses (i.e. hepatitis B, hepatitis C, HIV). • Discard MDVs when the beyond-use date has been reached, when doses are drawn in a patient treatment area, or any time the sterility of the vial is in question! 9
  • 10. Prefilled syringes ✓ A prefilled syringe is a single-dose packet of parental drug to which a needle has been fixed by the manufacturer. ✓ Prefillable syringes have become an increasingly important option in the packaging and delivery of injectable drug products. ✓ Humira®, Enbrel®, Copaxone®, Lovenox® and Rebif® are examples of blockbuster drugs that are being extensively administered via prefilled syringes 10
  • 11. Vehicles for Injection • Aqueous vehicles: • Frequently, isotonic (to blood) to which drug may be added at time of use. • Water-miscible vehicles: • Portion of the vehicle in the formulation, • used primarily to effect solubility of drugs and/or reduce hydrolysis • ethyl alcohol; polyethylene glycol (liquid) and propylene glycol • Nonaqueous vehicles: • Fixed oils (vegetable origin, and rancid resistance) used in hormone preparations 11
  • 12. Aqueous vehicles • Water for Injection (WFI) USP • Sterile Water for Injection (SWFI) • Bacteriostatic Water for Injection USP • Sterile Water for Irrigation USP • Sterile Water for Inhalation USP 12
  • 13. Water for Injection (WFI) USP • Highly purified water used as a vehicle for injectable preparations which will be subsequently sterilized. • USP requirement: NMT 10 ppm (1 mg/100 ml) of total solids. • pH of 5.0 – 7.0 . • WFI may be prepared by either distillation or reverse osmosis. • Stored in chemically resistant tank. • Used as solvent for preparation of parenteral solutions. • It is not required to be sterilized and pyrogen free. • It is intended to be used within 24 hours after collection. • The water should be collected in sterile and pyrogen free containers. 13 Specifications for WFI as per USP
  • 14. Sterile Water for Injection (SWFI) • Sterile Water for Injection is Water for Injection packaged and rendered sterile. • Is water for injection that is sterilized and packaged in single dose container of type1 and 2 glass. • It is used for extemporaneous prescription compounding and as a sterile diluent for parenteral products. • It may also be used for other applications when • Access to a validated water system is not practical, or • Where only a relatively small quantity is needed. • Sterile Water for Injection is packaged in single-dose containers not larger than 1 L. • Multiple- dose containers not exceeding 30 ml. • They are permitted to contain higher levels of solid than WFI because of possible leaching. • Used for washing wounds, surgical incisions or body tissues. 14 Why TDS in SWFI is more than WFI?
  • 15. Bacteriostatic Water for Injection USP • Water for Injection, packaged and rendered sterile, to which one or more suitable antimicrobial preservatives are added or Is sterile water for injection that contains one or more suitable antimicrobial agents. • Sterile water containing 0.9% benzyl alcohol that is used to dilute or dissolve medications. • It is intended to be used as a diluent in the preparation of parenteral products. • These are typically for multi-dose products that require repeated content withdrawals. • It also packaged in single or multiple dose container of type 1 and 2 glass. • It may be packaged in single-dose or multiple-dose containers not larger than 30 mL. 15
  • 16. Sterile Water for Irrigation USP • Water for Injection packaged and sterilized in single-dose containers which may be larger than 1 L. • Is water for injection that is sterilized and suitably packaged. • They allow rapid delivery of their contents. • Due to its usage, Sterile Water for Irrigation is not required to meet Particulate Matter in Injections. • It contains no antimicrobial agents or other added substances. 16
  • 17. Sterile Water for Inhalation USP • Is Water for Injection that is packaged and rendered sterile. • It is intended for use in inhalators and in the preparation of inhalation solutions. • This monograph has no requirement to meet. • It carries a less stringent specification for bacterial endotoxins than Sterile Water for Injection. • Therefore is not suitable for parenteral applications. 17
  • 18. Water-miscible vehicles • A number of solvents that are miscible with water have been used as a portion of the vehicle in the formulation of parenterals. • These solvents are used to solubilize certain drugs in an aqueous vehicle and to reduce hydrolysis. • The most important solvents in this group are ethyl alcohol, liquid polyethylene glycol and propylene glycol. • Ethyl alcohol is used in the preparation of solutions of cardiac glycosides and the glycols in solutions of barbiturates, certain alkaloids, and certain antibiotics. • Such preparations are given intramuscularly. 18
  • 19. Water-miscible vehicles • There are limitations with the amount of these co-solvents that can be administered, due to toxicity concerns, greater potential for hemolysis, and potential for drug precipitation at the site of injection. • Formulation scientists needing to use one or more of these solvents must consult the literature and toxicologists to ascertain the maximum amount of co-solvents allowed for their particular product. 19
  • 20. Non-Aqueous Vehicles • The most important group of non-aqueous vehicles is the fixed oils. • The USP provides specifications for such vehicles, indicating that the fixed oils must be of vegetable origin so they will metabolize, will be liquid at room temperature, and will not become rancid readily. • The USP also specifies limits for the free fatty acid content, iodine value, and saponification value (oil heated with alkali to produce soap, i.e., alcohol plus acid salt). • The oils most commonly used are corn oil, cottonseed oil, peanut oil, and sesame oil. 20
  • 21. Non-Aqueous Vehicles • Fixed oils are used as vehicles for certain hormone (e.g., progesterone, testosterone, deoxycorticosterone) and vitamin (e.g., Vitamin K, Vitamin E) preparations. • The label must state the name of the vehicle, so the user may beware in case of known sensitivity or other reactions to it. 21
  • 22. 22 Antimicrobials • Added for fungistatic or bacteriostat action or concentration. • Used to prevent the multiplication of micro-organisms. • Examples: • Benzyl alcohol -- 0.5 – 10 % • Benzethonium chloride -- 0.01 % • Methyl paraben -- 0.01 – 0.18 % • Propyl paraben -- 0.005 – 0.035 % • Phenol -- 0.065 – 0.5 % Preservatives  Multidose containers must have preservatives unless prohibited by monograph.  Large volume parenteral must not contain preservative b’coz it may be dangerous to human body if it contain in high doses.
  • 23. 23 Antioxidants • Used to protect product from oxidation. • Acts as reducing agent or prevents oxidation. A) Reducing agent:  Ascorbic acid -- 0.02 – 0.1 %  Sodium bisulphate -- 0.1 – 0.15 %  Sod. Metabisulphite -- 0.1 – 0.15 %  Thiourea -- 0.005 % C) Synergistic:  Ascorbic acid ,  Citric acid ,  Tartaric acid. B) Blocking agents:  Ascorbic acid esters -- 0.01 – 0.015%  BHT -- 0.005 – 0.02 % D) Chelating agent:  EDTA -- 0.01- 0.075 % Example
  • 24. 24 Buffers• Added to maintain pH, • Change in pH may causes degradation of the products • Acetates, citrates, phosphates are generally used. Factors affecting selection of buffers: • Effective range, • Concentration • Chemical effect on the total product Examples: • Acetic acid, adipic acid, benzoic acid, citric acid, lactic acid • Used in the conc. of 0.1 to 5.0 %
  • 25. 25 Stabilizers • As parenterals are available in solution form they are most prone to unstabilize. • Used to stabilize the formulation • Maintain stable Examples: • Creatinine – 0.5- 0.8 % • Glycerin – 1.5 – 2.25 % • Niacinamide – 1.25 -2.5 % • Sodium saccharin – 0.03 % • Sodium caprylate – 0.4 %
  • 26. 26 Chelating agents • Used to form the complex with the metallic ions present in the formulation so that the ions will not interfere during mfg. of formulation. • They form a complex which gets dissolved in the solvents. Examples: • Disodium edetate – 0.00368 - 0.05 % • Disodium calcium edetate - 0.04 %
  • 27. 27 Solubilizing agents • Used to increase solubility of slightly soluble drugs • They acts by any one of the following: • Solubilizers, • Emulsifiers or • Wetting agents. Examples: • Dimethylacetamide, Ethyl alcohol, Glycerine, Lecithin, PEG – 40 + Castor oil, PEG – 300, Polysorbate 20, 40, 80
  • 28. 28 Inert gases • Another means of enhancing the product integrity of oxygen sensitive medicaments is by displacing the air the solution with nitrogen or argon. • This technique may be made more effective by first purging with nitrogen or boiling the water to reduce dissolved oxygen. • The container is also purged with nitrogen or argon before filling and may also be topped off with gas before sealing.
  • 29. 29 Tonicity adjusting agents • Used to reduce the pain of injection. • Buffers may acts as tonicity contributor as well as stabilizers for the pH. • Isotonicity depends on permeability of a living semipermeable membrane • Hypotonic : swelling of cells (enlargement) • Hypertonic: shrinking of cells (reduction) Examples: • Glycerin, Lactose, Mannitol, Dextrose, Sodium chloride, Sorbitol
  • 30. 30 Surfactants • Used: • to dispose a water-insoluble drug as a colloidal dispersion. • for wetting powder. • to prevent crystal growth in a suspension. • to provide acceptable syringability. • for Solubilizing steroids and fat-soluble vitamins. • Example: • Polyethylene 0.1 to 0.5% • Sorbitan monooleate 0.05 to 0.25%
  • 31. 31 Protectants • Used to protect against loss of activity caused by some stress • Used to prevent loss of active ingredients by adsorption to process equipment or to primary packaging materials • Protectants primarily used in protein formulations. Examples: • Sucrose, glucose, lactose, maltose, trehalose (2 to 5%) • Human serum albumin (0.1 to 1%)
  • 32. Processing and manufacturing of SVPs • The production area where the parenteral preparation are manufactured can be divided into five sections: • Clean-up area • Preparation area • Aseptic area • Quarantine area • Finishing & packaging area 32
  • 33. Layout showing various activities in parenteral manufacturing 33
  • 34. Clean- up area • Non aseptic area. • Free from dust, fibers and micro-organisms. • Constructed in such a way that should withstand moisture, steam and detergent. • Ceiling and walls are coated with material to prevent accumulation of dust and micro-organisms. • Exhaust fans are fitted to remove heat and humidity. • The area should be kept clean so as to avoid contamination to aseptic area. • The containers and closures are washed and dried in this area. 34
  • 35. Preparation area • The ingredients are mixed and preparation is prepared for filling. • Not essential that the area is aseptic. • Strict precaution is taken to prevent contamination from outside. • Cabinets and counters: SS. • Ceiling and walls : sealed and painted. 35
  • 36. Aseptic area • Filtration and filling into final containers and sealing is done. • The entry of outside person is strictly prohibited. • To maintain sterility, special trained persons are only allowed to enter and work. • Person who worked should wear sterile cloths. • Should be subjected for physical examination to ensure the fitness. • Minimum movement should be there in this area. • Ceiling and walls and floors : sealed and painted or treated with aseptic solution and there should not be any toxic effect of this treatment. • Cabinets and counters: SS. • Mechanical equipments : SS. 36
  • 37. Air in aseptic area • Free from fibers, dust and micro organisms. • HEPA filters are used which removes particles upto 0.3 micron. • Fitted in laminar air flow system, in which air is free from dust and micro organisms flows with uniform velocity. • Air supplied is under positive pressure which prevents particulate contamination from sweeping. • UV lamps are fitted to maintain sterility. 37
  • 38. Quarantine area • After filling, sealing and sterilization the products or batch is kept in this area. • The random samples are chosen and given for analysis to QC dept. • The batch is send to packing after issuing satisfactory reports of analysis from QC. • If any problem is observed in above analysis the decision is to be taken for reprocessing or others. 38
  • 39. Finishing and packaging area • After proper label, the product is given for packing. • Packing is done to protect the product from external environment. • The ideal Packing is that which protects the product during transportation, storage, shipping and handling. • The labeled container should be packed in cardboard or plastic containers. • Ampoules should be packed in partitioned boxes. 39
  • 40. Stainless steel used in Pharm. Industry 40
  • 41. Stainless steel used in Pharm. Industry 41